cyrilzakka/clinical-trials huggingface dataset:
Influence of Low-level Laser Therapy Versus Low-intensity Pulsed Ultrasound on Different Orthodontic Tooth Movements

The aim of this prospective clinical project will be to compare the effect of low-level laser therapy versus low intensity pulsed ultrasound on the rate of different orthodontic tooth movements

The aim of this prospective clinical project will be to compare the effect of low-level laser therapy versus low intensity pulsed ultrasound on the rate of different orthodontic tooth movements, specifically; canine retraction, incisors' leveling and alignment, maxillary molar distalization, and incisors' intrusion

Eligibility Criteria:
Inclusion Criteria:

- A- leveling and alignment Eligibility criteria

1. Age ranges from 14 to 17 years. 2. Bilateral Class II molar relationship. 3. Skeletal Class I or mild Class II relationship. 4. Normal or decreased vertical height. 5. No posterior crowding or spaces. 6. Fully erupted maxillary first and second molars. 7. Congenitally missing or extracted third molars. 8. Good oral hygiene. 9. Absence of any periodontal disease and alveolar bone loss. 10. Absence of medications that may inhibit orthodontic movement

Lower incisor leveling and alignment Inclusion criteria Complete permanent dentition (third molars not included); Moderate mandibular anterior crowding (with little's irregularity index score greater than 4 mm) who required non-extraction approach in the mandibular arch; No tooth size, shape or root abnormalities visible on the patient's radiographic records; No spaces in the mandibular arch; No blocked out tooth that did not allow for placement of the bracket at the

initial bonding appointment; 6. No required management with interproximal stripping, inter-maxillary elastics, open NiTi springs, and removable or extra-oral devices. Canine retraction Eligibility criteria

Age, 15 to 25 years; Class ii division 1 malocclusion with mild or no crowding; No previous orthodontic treatment; No systemic disease that might have affected bone formation or density, such as osteoporosis, hyperparathyroidism, or vitamin d deficiency; Adequate oral hygiene; Probing depth values not exceeding 3 mm across the Entire dentition; Adequate thickness of the attached gingiva (1-2 mm); No radiographic evidence of bone loss

Exclusion Criteria:

- Patients who required surgery to correct skeletal discrepancies. Patients with congenital dentoskeletal disorders. Missed or mutilated teeth in maxillary arch. Patients with poor oral hygiene and/or periodontally compromised patients Severe dental crowding that necessitates an extraction approach 2. Abnormal anteroposterior and vertical relationships; 3. Patients with cleft lip and palate, anomalies, and syndromes; 4. Previous orthodontic 5. Treatment; 6. Regular medications intake that could interfere with otm. -
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

The purpose of this study is to determine the safety and effectiveness of a treatment regimen using Zevalin® plus Rituxan® for patients who have low grade Non-Hodgkin's Lymphoma (NHL) or relapsed Non-Hodgkin's lymphoma and have been previously treated. This study will use an experimental scheduling regimen. No chemotherapy will be used in this study.

The objective of this study is to determine overall response rate, event-free survival, time-to-progression, time-to-next-therapy, and freedom-from-relapse in patients with low-grade lymphoma in first or second relapse treated with Zevalin followed by 2 years of Rituxan maintenance therapy in a multicenter, community-based setting, as well as evaluate relative response rates in populations with and without prior rituximab therapy, in first versus second relapse, and with and without bulky (\> 5 cm in greatest diameter) disease.

To meet the initial trial enrollment goal of 300 patients over two years, 42 total sites were activated. The study has subsequently closed to accrual. Currently 8 sites remain active to follow the 12 subjects enrolled in the past year.

Eligibility Criteria:
Inclusion Criteria:

* Follicular non-Hodgkin's lymphoma including SLL in first or second relapse.
* No anticancer therapy for three wks (six wks if nitrosourea or Mitomycin C); not rituximab refractory.
* Age \>= 18 years, not pregnant or lactating.
* Expected survival \>= 3 mths; PS 0, 1, or 2.
* ANC \>= 1,500/mm3, platelet counts \>= 100,000/mm3.
* Total bilirubin \> 2.0 mg/dL, creatinine \> 2.0 mg/dL.
* Total lymphocyte count \< 5,000/mm3 for SLL.
* \<25% bone marrow involvement with lymphoma.

Exclusion Criteria:

* Prior ABMT or ASCT, hypocellular or marked reduction in bone marrow precursors, or history of failed stem cell collection.
* Bulky areas of disease more than 10 cm in diameter.
* Patients with CLL, CNS, or mantle cell lymphoma.
* Hx of HIV/AIDS related lymphoma, hepatitis B or C.
* Prior radioimmunotherapy or XRT to \>25% of active bone marrow.
* G-CSF or GM-CSF within 2 wks, pegylated G-CSF within 4 wks of treatment
The Efficacy of a Probiotic Product on Acute Upper Respiratory Tract Infections (Common Cold) in Healthy Children

The aim of the present study is to test the efficacy of the combination of two probiotic bacteria in reducing the severity of upper respiratory tract infections (common cold) in healthy children attending day care or school. The probiotic bacteria used are Lactobacillus plantarum strain DSM 15312 and Lactobacillus paracasei DSM 13434 at a total dose of 1 x 10\^9 CFU/tablet and day and will be consumed for a period of 12 weeks.


Eligibility Criteria:
Inclusion Criteria:

1. Parents / legal guardians signed written informed consent to participate in the study.
2. Healthy children (male and female) aged 3 to 7 years old (inclusive) at enrollment.
3. Children attending day care center or school.
4. No consumption of commercial products containing probiotics during the whole study period.
5. Children not being intensive consumers of regular yoghurts (no more than one 125 g serving per day).
6. Ability of the parents / legal guardians (in the Investigator's opinion) to comprehend the full nature and purpose of the study.
7. Parents' / legal guardians' consent to the study and willing to comply with all its procedures.

Exclusion Criteria:

Children presenting one or more of the following criteria will not be eligible to enter the study.

1. Flu vaccine administration within the last 3 months prior to enrollment.
2. Use of antibiotics within the last 30 days prior to enrollment.
3. Acute infection or fever at enrollment.
4. Any congenital or chronic disease that in the opinion of the investigator would adversely affect the results of the study.
5. Any kind of immunodeficiency or allergy (including known food allergy).
6. Subjects with known hypersensitivity or allergy to any component of the study products.
7. Significant illness within the 2 weeks prior to the enrollment or any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study.
8. Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study.
Bone Health in Pregnancy

Women between the ages of 18 and 45 are needed for a study that looks at the effect of calcium supplementation on bone health during pregnancy in black and white women. Study subjects will be divided into two groups. Each group will take 2 study supplements each day, the supplement will be calcium or placebo (a pill without calcium). The study involves five visits to the Children's Hospital of Oakland Research Institute; each visit will be 1-2 hours in length. There are 3 study visits during pregnancy and 2 in the first year after delivery. At each visit you will have your blood drawn and be asked questions about what you eat and what type of activities you do. At visit 16 and 36 weeks and 4 and 12 months postpartum you will have your bone density measured. You will be paid $240 for completing the study.

Women between the ages of 18 and 45 are needed for a study that looks at the effect of calcium supplementation on bone health during pregnancy in black and white women. Study subjects will be divided into two groups. Each group will take 2 study supplements each day, the supplement will be calcium or placebo (a pill without calcium). The study involves five visits to the Children's Hospital of Oakland Research Institute; each visit will be 1-2 hours in length. There are 3 study visits during pregnancy and 2 in the first year after delivery. At each visit you will have your blood drawn and be asked questions about what you eat and what type of activities you do. At visit 16 and 36 weeks and 4 and 12 months postpartum you will have your bone density measured. You will be paid $240 for completing the study.

Eligibility Criteria:
Inclusion Criteria:

* First trimester of pregnancy
* Between the age of 18-45

Exclusion Criteria:

* Smoke
* Prepregnancy BMI \>35
* Medical condition that will affect bone
* Takes a medication that affects bone
A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects

PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male and/or female subjects between the ages of 18 and 55 years
* Body Mass Index (BMI) of 26.5 to 35.5 kg/m2; and a total body weight \>50 kg (110 lbs).

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening.
Identifying Coping Strategies of Patients With Cancerous Wound After a Specific Nursing Accompaniment

This is a first care research focuses on the study of adaptation strategies implemented by cancerous wound patients. Today, advances in treatment generally increases the life expectancy of a patient with cancer. the patients thus live longer with their wound. How to live then? The literature review shows that there is research on adaptation strategies in cancer pathology and that different factors seem to interact with these strategies. However the investigators have not found written on the theme cancerous wound and adaptation strategies.

the investigators conducted a pilot study of this research in medical oncology, Prof. service Duffaud CHU Timone, which allowed us to highlight patient adherence and motivation centers contacted but also areas for improvement. Indeed, the investigators now were doing a study of adaptation strategies implemented by the patient time T of his life. However, adaptation is a process in constant motion, the investigators want to identify two different time patients coping strategies following a specific charge nurse taking.


Eligibility Criteria:
Inclusion Criteria:

* Adult patient
* Patient having at least a cancerous wound.
* Patient having read the information leaflet and has given its consent.
* Patient able to meet a French language questionnaire.

Exclusion Criteria:

* History or active psychiatric illness.
* Unable to give informed consent.
* Inability to comply with the protocol procedures for geographical, social or psychological.
Effects of Different Electrophysical Agents in Hamstring Muscles Flexibility of Healthy Individuals

Sixty healthy individuals will be randomised into four groups. Group I (15 subjects) will be applied hotpacks, Group II (15 subjects) will be applied infrared, Group III will be applied ultrasound to hamstring muscles for 18 sessions 3 times per week and the subjects will do hamstring self stretching exercise 3 times for 15 seconds. Group IV will only do self stretching exercises.

Outcome measures are Range of Motion and hamstring flexibility. Measurements will record before and after the end of the treatment.

Inclusion criteria for the study are; being student of Saraykoy Vocational School, Active knee extension degree must be lower than 60 when the hip flexed to 90 degree. Exclusion criteria are; undergoingsurgery for knee pathologies, having a systemic and inflammatory disease targeting this region, having a knee disorder, pregnancy, malignancy, doing regularly another exercise programme. According to our criteria 60 participants will be randomised into four groups. Group 1 will receive 20 minutes hotpacks and will do hamstring self stretching exercise 3 times for 15 seconds. Participants will do self stretching hamstring exercise at supine position lying and they will use a band for stretching. Group II will receive 20 minutes infrared at prone position and will do self stretching exercise 3 times for 15 seconds. Participants will do self stretching hamstring exercise at supine position lying and they will use a band for stretching.

Group III will receive 5 minutes 1MHz ultrasound therapy and will do self stretching exercise for 18 sessions 3 times per week. Participants will do self stretching hamstring exercise at supine position lying and they will use a band for stretching 3 times for 15 seconds. Group IV will do only hamstring self stretching exercise therapy for 18 sessions 3 times per week. Participants will do self stretching hamstring exercise at supine position lying and they will use a band for stretching 3 times for 15 seconds. Outcome measures are Range of Motion and hamstring flexibility. Range of Motion will be assed by using universal goniometer for knee and hip joints. Hamstring flexibility will be assed with active knee extension test by using universal goniometer. All measurements will done 3 times and average of scores will be taken. Outcomes will be recorded before and after the end of the treatment. All assessments were made by the same researcher before and after treatment.

Eligibility Criteria:
Inclusion Criteria:

* Being Student in Saraykoy Vocational School
* Having Active Knee Extension degree lower than 60

Exclusion Criteria:

* undergoing surgical operation for knee pathologies
* history of trauma involving knee joint region
* having a systemic and inflammatory disease targeting this region
* pregnancy
* malignancy
* doing another exercise programme
Continuous Vs Intermittent Ketorolac for Pain Control in Peds CV Surgery

The proposed study will be a prospective, randomized, double blind, placebo controlled trial to compare the use of a continuous infusion versus intermittent ketorolac on postoperative patients in the pediatric cardiovascular ICU. We intend to determine if the continuous infusion leads to a decreased utilization of opiates when compared to intermittent ketorolac.

The mainstay of postoperative pain control in the CVICU remains opiate-based therapy. Reliance on this class of medications can be detrimental, contributing to complications including hemodynamic instability, dependency, and withdrawal which can ultimately lead to longer hospital admissions, as well as long term and persistent neurodevelopmental effects. In addition, the opioid crisis has driven practitioners to aim for methods to reduce opioid exposure and post-operative narcotic prescriptions in pediatric and adult patients alike. There is a growing body of evidence in the adult literature showing promising results with the use of a continuous infusion of ketorolac in postoperative patients, including in a pediatric population. What the current literature has failed to show is whether a continuous infusion of ketorolac post operatively decreases the use of opiate mediations in a pediatric population compared to intermittent bolus injections, which is the current standard of care. Given the sensitivity and fragility inherent in those patients with CHD, working to reduce deleterious effects from excessive and prolonged opiate exposure is imperative. This study aims to examine whether the use of a continuous infusion of ketorolac can reduce the amount of opiates needed to treat postoperative pain control in the pediatric CVICU population, in comparison to patients who receive intermittent ketorolac within the first 72 hours post-operatively.

Eligibility Criteria:
Inclusion Criteria:

1. All patients aged 3 months to 4 years 11months admitted post operatively to the CVICU during the time period in which the study will be ongoing
2. Initiation of study medication within the first 12-24 hours post-operatively
3. The cardiovascular attending of record after review of the intraoperative course and post-operative laboratories determines the patient will receive Ketorolac for pain control

Exclusion Criteria:

1. Patients that have acute kidney injury, as defined by the letter "I" in the pRIFLE criteria.
2. History of allergy or sensitivity reaction to ketorolac or any NSAID medications.
3. Requiring mechanical circulatory support (ECMO) or continuous renal replacement therapy (CRRT) within the first 48 hours post-operatively
4. Orthotopic heart transplantation
5. Clinically significant bleeding
6. Patients with known pre-operative medical renal disease, renal transplantation history, congenital or acquired renal abnormality or deformity
Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients

There is currently no effective treatment of bronchiectasis other than treating its complications such as infection, bleeding, etc. Roflumilast is a newly developed anti-inflammatory drug that has proven to be effective in stable COPD. We hypothesized that Roflumilast might be effective in symptomatic bronchiectasis patients


Eligibility Criteria:
Inclusion Criteria:

* Bronchiectasis on CT
* chronic (\>3 months) cough or sputum

Exclusion Criteria:

* needs hospitalization
* life expectancy of less than six months
* pregnancy or breast feeding
* history of acute respiratory infection within 4 weeks
* history of taking antibiotics within 4 weeks
* active hemoptysis
* %predicted FEV \< 30%
* severe liver disease (Child Pugh Class B or C)
Development of a Predictive Index for Probable Depression Among Secondary School Students

The present study aims to develop a new predictive index to predict future depression of adolescents by using factors including individual, interpersonal and environmental. The index can be used to predict likelihood of students who are non-probable depression cases convert into probable depression cases. In addition, the investigators also test the factors of depression remission. It can hence be used in school setting to identify high-risk students, and provide them with secondary interventions that are designed by considering modifiable significant variables identified in this unique, large-scale, longitudinal study.

A 12-month longitudinal study will be conducted in secondary school settings.

The investigators will investigate incidence of probable depression (i.e., from non-depression, CESD\<16, at baseline to probable depression, CESD≥16, at month 12) and remission of probable depression.

The investigators will investigate factors that can prospectively predict new cases/remission of probable depression, including both well-documented risk/protective factors and some under-examined but potentially important local factors (e.g. school/academic stress, psychological resilience). The relative importance of the risk/protective factors at different socio-ecological levels will be compared and their combined effect will be identified.

Based on the selected factors, the investigators will derive a new prediction index called the Adolescent Depression Prediction Index (ADPI) in a model building sample and test its performance in predicting incidence of depression in a validation sample among secondary school students in Hong Kong.

Eligibility Criteria:
Inclusion Criteria:

* Secondary 1 (seventh year of formal education) to Secondary 4 Chinese students, who are studying local mainstream schools in Hong Kong.
* Able to read Chinese and speak either Cantonese or Mandarin.

Exclusion Criteria:

* Eligible students whose parents refuse to give consent to take part in the study.
Carefully seLected and Easily Accessible at No Charge Medications

This trial evaluates the effect of providing primary care patients with free and convenient access to a set of essential medicines. Half of the participants will receive free and convenient access to these essential medicines, while the other half will have usual access to medicines.

Medication adherence is one important determinant of health outcomes. Approximately one half of treatments for chronic disease are not taken as directed. Cost is one of several important causes of poor adherence and it is particularly important for vulnerable people.

The size of many formularies makes it difficult for clinicians to know the safest and most effective medications to prescribe. This may partially explain poor medication selection. Short lists of essential medications have improved the the quality of prescribing.

Eligibility Criteria:
Inclusion Criteria:

* Cost related medicine non-adherence during last 12 months

Exclusion Criteria:

* Family member living at same address of patient who is already enrolled in this trial
* Patient joined practice during last 6 months